42 results on '"van der Kwast, T.H."'
Search Results
2. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019?
3. FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
4. Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study
5. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis
6. 1074 - FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
7. Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis
8. Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma
9. PT008 - What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis
10. 611 Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy
11. 115 Gleason score reclassification of men with classical Gleason score ≤6 who eventually died of prostate cancer in the ERSPC Rotterdam
12. 423 Functional role of the kallikrein 6 region of the kallikrein locus in genetic predisposition for aggressive (Gleason ≥8) prostate cancer: Fine-mapping and methylation study in a Canadian cohort and the Swiss arm of the European Randomized Study for Prostate Cancer Screening
13. 755 A five-gene DNA-methylation biomarker panel sensitively detects bladder cancer and discriminates between high-grade and low-grade disease in voided urine
14. 20 Creation of the Toronto Biopsy Avoidance Tools (T-BAT) with clinical parameter-only and adipokine biomarker-augmented versions
15. 128 - Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis
16. 852 Prostate biopsy trends in relation to U.S. Preventative Task for recommendations against routine PSA-based screening: A time-series analysis
17. 206 Fine-mapping of the Kallikrein region and its role in prostate cancer aggressiveness: Results from a Canadian cohort and the European Randomized Study for Prostate Cancer Screening
18. 890 Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men
19. 45 The role of enhancer RNAs in regulating differentially expressed pathological grade associated genes in urothelial bladder cancer – results from a whole transcriptomal analysis
20. P074 - Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma
21. 588 Initial results of MR guided laser focal therapy for prostate cancer
22. 988 Obesity associated with larger prostate volume but not with worse urinary symptoms: Analysis of a large cohort undergoing trans-rectal ultrasound
23. 50 Silencing Notch-1 and Notch-3 promotes epithelial-to-mesenchymal transition (EMT) and self-renewal potential in human bladder cancer
24. 543 Methylation of Kallikrein-related peptidases as novel diagnostic and prognostic biomarkers for prostate cancer
25. 1122 Prevalence of prostate carcinoma and its precursor lesions in Russian Caucasian and Japanese men in autopsy specimens: A prospective comparative international study with central pathology review
26. 1092 5-alpha reductase inhibitors diminish the rate of progression in men with low risk prostate cancer on active surveillance
27. 154 COULD SCREENING FOR BLADDER CANCER PRODUCE A STAGE MIGRATION TOWARDS DETECTION OF NON-MUSCLE-INVASIVE CANCERS?
28. 542 YOUNG PATIENTS (≤40 YEARS) PRESENTING WITH BLADDER CANCER, WHAT CAN WE EXPECT
29. 172 INVESTIGATING THE RISK OF BLADDER CANCER AMONG HEREDITARY NON-POLYPOSIS COLORECTAL CANCER (HNPCC) PATIENTS WITH CONFIRMED MISMATCH REPAIR (MMR) GENE MUTATIONS
30. 52 COMPARISON OF MOLECULAR MARKERS, SUB-STAGE AND THE EORTC RISK-SCORE TO PREDICT CLINICAL OUTCOME OF PT1 BLADDER CANCER
31. 321 RADICAL CYSTECTOMY OUTCOME AND PROGNOSTIC PARAMETERS – COMBINED RESULT FROM TWO LARGE SERIES
32. 51 MOLECULAR MARKERS SHOW DIFFERENCES IN BIOLOGICAL POTENTIAL PER GRADE CATEGORY FOR THE WHO 1973 AND 2004 CLASSIFICATION SYSTEMS: A LARGE MULTI-CENTER STUDY WITH CENTRAL PATHOLOGY REVIEW IN NON-MUSCLE INVASIVE BLADDER CANCER
33. 195 IMPACT OF SUB-STAGE ON THE CLINICAL OUTCOME OF PT1 BLADDER CANCER
34. 1016 CYSTOSCOPY REVISITED AS THE GOLD STANDARD FOR DETECTION OF BLADDER CANCER RECURRENCES: DIAGNOSTIC REVIEW BIAS IN A PROSPECTIVE RANDOMISED TRIAL
35. 308 THE FGFR3 MUTATION IS RELATED TO FAVORABLE PT1 BLADDER CANCER
36. 672 IMPACT OF SUB-STAGE AND PATHOLOGY REVIEW ON THE CLINICAL OUTCOME OF PT1 BLADDER CANCER
37. 1005 AN FGFR3 MUTATION IN CELLS OBTAINED FROM VOIDED URINE IS A STRONG PREDICTOR OF RECURRENT BLADDER CANCER
38. 645 LONG-TERM FOLLOW-UP FOR PRIMARY T1 HIGH-GRADE BLADDER CANCER. DOES BCG REALLY PREVENT PROGRESSION?
39. 299 ANDROGEN RECEPTOR (AR) AND BLADDER CANCER: A LARGE BI-INSTITUTIONAL STUDY ON 473 PATIENTS
40. SHOULD WE REPLACE THE GLEASON SCORE WITH THE AMOUNT OF HIGH-GRADE CANCER?
41. METASTATIC DISEASE RATES AFTER RADICAL PROSTATECTOMY AND RADIOTHERAPY IN SCREEN-DETECTED PROSTATE CANCER
42. 614 - Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.